Stahl-Pehe Anna, Selinski Silvia, Bächle Christina, Rosenbauer Joachim
Institute for Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes Research, Auf'm Hennekamp 65, 40225, Düsseldorf, Germany.
German Center for Diabetes Research (DZD), Munich-Neuherberg, Germany.
Diabetol Metab Syndr. 2021 May 19;13(1):55. doi: 10.1186/s13098-021-00673-0.
This study aims to analyze the patient-reported outcome (PRO) of treatment satisfaction in a sample of children, adolescents and young adults with long-duration type 1 diabetes and to determine potential risk factors for poor treatment satisfaction and the intraindividual changes over a 3-year period.
This study used data from two population-based questionnaire surveys conducted in 2015-2016 and 2018-2019. The participants were 11 to 27 years old and had a type 1 diabetes duration of 10 years or longer in 2015-2016 (n = 575). Factors that were potentially associated with poor treatment satisfaction (moderate, poor or very poor) compared to the reference group (very good or good treatment satisfaction) were analyzed by log binomial regression adjusted for sex and age group.
In 2015-2016 (2018-2019), 26% (33%) of the respondents rated their diabetes treatment/consultation as "very good", 53% (46%) as "good", and 20% (21%) as "poor". Based on the 2018-2019 data, girls/women had an increased risk of poor treatment satisfaction (RR: 1.64 (1.10; 2.44), p = 0.016). In addition, people with hemoglobin A1c (HbA1c) values ≥ 7.5% had a more than twice the risk of poor treatment satisfaction than people with HbA1c values < 7.5% (RR: 2.43 (1.63; 3.63), p < 0.001). A total of 42% of people with poor treatment satisfaction in 2015-2016 also reported poor treatment satisfaction at follow-up.
Most study participants were satisfied with their diabetes treatment. However, we identified risk groups that would benefit from targeted interventions to improve this important PRO.
本研究旨在分析患有长期1型糖尿病的儿童、青少年和年轻成年人样本中患者报告的治疗满意度结果,并确定治疗满意度低的潜在风险因素以及个体在3年期间的变化情况。
本研究使用了2015 - 2016年和2018 - 2019年进行的两项基于人群的问卷调查数据。参与者年龄在11至27岁之间,在2015 - 2016年1型糖尿病病程达10年或更长(n = 575)。通过对性别和年龄组进行调整的对数二项回归分析,比较与参照组(治疗满意度非常好或好)相比,可能与治疗满意度低(中等、差或非常差)相关的因素。
在2015 - 2016年(2018 - 2019年),26%(33%)的受访者将他们的糖尿病治疗/咨询评为“非常好”,53%(46%)评为“好”,20%(21%)评为“差”。基于2018 - 2019年的数据,女孩/女性治疗满意度低的风险增加(相对风险:1.64(1.10;2.44),p = 0.016)。此外,糖化血红蛋白(HbA1c)值≥7.5%的人治疗满意度低的风险是HbA1c值<7.5%的人的两倍多(相对风险:2.43(1.63;3.63),p < 0.001)。2015 - 2016年治疗满意度低的人中有42%在随访时也报告治疗满意度低。
大多数研究参与者对他们的糖尿病治疗感到满意。然而,我们确定了一些风险群体,这些群体将从针对性干预中受益,以改善这一重要的患者报告结果。